(balsalazide disodium) Capsules 750 mg, is an anti-inflammatory drug approved for the treatment of mildly to moderately active ulcerative colitis.
Salix Pharmaceuticals, Ltd., Raleigh, North Carolina, announced that the FDA granted Colazal
(balsalazide) additional marketing exclusivity until January 8, 2007.
Two other agents in this class, balsalazide (Colazal
) and olsalazine (Dipentum), are broken down in the colon to 5-ASA.
The product is available in bottles of 280 capsules and is AB-rated to Colazal
. According to the company, annual sales of the brand product in the 750-mg dosage are about $132 million.